A 2021 study found that Tucidinostat induces apoptosis in DLBCL cells by targeting the HDACs/STAT3/Bcl-2 pathway, while Abexinostat has proven effective in relapsed or refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.